Anastasia Pouli

Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide

Meletios Α. Dimopoulos, Athanasios K. Anagnostopoulos, Marie‐Christine Kyrtsonis et al. · Journal of Clinical Oncology · 2007 · 277 citations · Full text

Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance

V. Eleutherakis-Papaiakovou, Aristotelis Bamias, Dimitra Gika et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2007 · 223 citations

Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐<i>κ</i>B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

Evangelos Terpos, Deborah J. Heath, Amin Rahemtulla et al. · British Journal of Haematology · 2006 · 219 citations · Full text

Sclerostin, Relapsed Multiple Myeloma, Immunology +17

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

Efstathios Kastritis, Konstantinos Zervas, Argiris Symeonidis et al. · Leukemia · 2009 · 187 citations

Hematological Malignancy, Oncology, Hematology +7

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy

Evangelos Terpos, Dimitrios Christoulas, Eirini Katodritou et al. · International Journal of Cancer · 2011 · 180 citations · Full text

Bone Disease, Abnormal Bone, Active Myeloma +15